Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | XmAb20717 |
Synonyms | |
Therapy Description |
XmAb20717 is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XmAb20717 | XmAb 20717|Vudalimab | CTLA4 Antibody 18 Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | XmAb20717 (Vudalimab) is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |